Effect of Acute Grape Seed Extract Supplementation on the Heart Rate Recovery in Young Individuals
Public ClinicalTrials.gov record NCT07137988. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study hypothesized that sustained sympathoexcitation via MMA slows down PHRR and that GSE supplementation is effective at improving PHRR in young individuals. 12 Participants were randomly assigned, via a double-blind, cross-over design, to either receive GSE (300mg, 2 capsules) or PL (300mg, 2 capsules), with a washout period of at least 72 hrs. between trials. A submaximal exercise test was performed using a cycle ergometer combined with isometric handgrip exercise using a handgrip dynamometer, and blood flow occlusion by placing a cuff over the brachial artery of the dominant arm. Post heart rate recovery (PHRR) was measured at 5 sec. intervals throughout the experiment. The PHRR was evaluated between GSE and PL at every min. for 300 sec.
Study identification
- NCT ID
- NCT07137988
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Interventions
- 600 mg grape seed extract Dietary Supplement
- 600 mg Starch Dietary Supplement
Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years to 30 Years
- Sex
- Male
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2, 2024
- Primary completion
- Dec 2, 2024
- Completion
- Dec 30, 2024
- Last update posted
- Aug 21, 2025
2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Baptist University | Riverside | California | 92504 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07137988, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2025 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07137988 live on ClinicalTrials.gov.